Unsere Webseite nutzt Cookies, damit die User-Experience gesteigert wird. Bitte beachten Sie, dass ohne Cookies einige Funktionalitäten nicht mehr ausführbar sind (z.B. Formulare). Ausführlichere Hinweise zu Cookies
OK
  1. CCRC-HaunerEN
  2. Technology platforms
  3. Pre-GMP Facility

Pre-GMP Facility

Bridge to Translation - Immunotherapy from Bench to Bed side

Cellular immunotherapy requires the set-up of GMP-compatible procedures.

The transfer of experimental methods to clinical scale cell engineering includes

  • Automation and up-scale of cell product manufacturing
  • Set-up and validation of quality control
  • Product characterization


For clinical scale cell engineering in a functionally closed system we chose the "CliniMACS Prodigy" device. It offers a platform for GMP-grade cell processing applications enabling fully automated washing, fractionation, cultivation, transduction and magnetic seperation of cells in a functionally closed system. 

The platform´s flexibility allows production of a wide range of cell products under S2 conditions. Further, automation within this device allows harmonization of cell-production processes in case of multicentric production strategies in clinical studies.

 


With the electroporator "GTx" (MaxCyte) we also have a GMP-compatible platform for the production of CRISPR/Cas-engineered cell therapy products, which can be combined with our existing platform via a tube system. The new range of non-viral "genetic engineering" processes enables the development of a wide variety of innovative T-cell therapy approaches.

Electroporation uses an electric field to temporarily make cell membranes permeable. CRISPR/Cas ribonucleoprotein complexes can be channelled into the cell interior through the resulting pores. In the process, DNA can be specifically modified at any point in the genome, allowing genes to be switched off (knock-out) or inserted (knock-in).



Set-up of the GMP-conform manufacturing process includes generation of SOP, selection of GMP-compatible reagents and up-scale of lab protocols. Pre-validation runs are performed in order to establish the manufacturing process, train staff and prepare production approval. 

"MACSQuant Analyzer" offers a GCP-compatible high-throughput platform for flow-cytometry-based quality control. With a range of automated features, this flow cytometer lays the foundation for standardization of analysis and gating procedures. 

  • Absolute quantification of cell populations allows dosing of cell products
  • Automation allows harmonization and standardization of quality control analyses in case of multicentric production 
  • Development of MACSQuant "Express Modes" offers fast and easy quality control analyses

Quality control strategies are set-up and validated in accordance to the requirements of regulatory authorities.

According to regulatory requirements cell products are pre-clinically characterized using established validation processes and infrastructures:

  • Specificity
  • Purity
  • Potency
  • Identity

Standardly, stability assays are perfomed in order to determine the shelf-life of the cell products. 

Dr. Theresa Käuferle

Head of Pre-GMP Facility

Executive Management

✉ Theresa.Kaeuferle@med.uni-muenchen.de

☎ 089-4400-52338

Dr. Ramona Krauß

Regulatory Affairs, Ethics and Biobanking

✉ Ramona.Krauss@med.uni-muenche.de

☎ 089-4400-52759

Christina Dietzer

Quality Management

✉ Christina.Dietzer@med.uni-muenchen.de

☎ 089-4400-52883


Prof. Tobias Feuchtinger

Dr. von Hauner Children´s Hospital

Head of Haematology/Oncology Department

✉ Kinderkrebszentrum@med.uni-muenchen.de

☎ 089-4400-52759

Lena Jablonowski

Doctoral Researcher (PhD track) 

✉ Lenamaria.Jablonowski@med.uni-muenchen.de

☎ 089-4400-57791

Teresa Augustin

Administration

✉ Teresa.Augustin@med.uni-muenchen.de

☎ 089-4400-54817

- 2 Patent Applications

- Stief TA, Kaeuferle T, Müller TR et al. Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021 May 28:S1525-0016(21)00303-8. doi: 10.1016/j.ymthe.2021.05.021

- Kaeuferle T et al. CRISPR-Cas9-Mediated Glucocortioid Resistance in Virus-Specific T cells for Adoptive T Cell Therapy Posttransplantation. Mol Ther. 2020 Jun 11:S1525-0016(20)30292-6. doi: 10.1016/j.ymthe.2020.06.002.

- Kaeuferle T et al. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019 Feb 6:12(1):13. doi: 10.1186/s13045-019-0701-1

Contact:

Dr. Theresa Käuferle

Head of Pre-GMP Facility

Dr. von Hauner Children´s Hospital

Dep. of Haematology/Oncology

Tel.: 089/4400-52338

E-Mail: Theresa.Kaeuferle@med.uni-muenchen.de